| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 251,147 | 3,959,999 | 3,985,754 | NaN |
| Total research and development expenses | 4,096,580 | 4,940,495 | 11,794,054 | NaN |
| Employee related costs | 731,673 | NaN | NaN | NaN |
| Stock-based compensation | 1,759,868 | NaN | NaN | NaN |
| Other general and administrative expenses | 1,290,436 | NaN | NaN | NaN |
| Total general and administrative expenses | 3,781,977 | 3,269,945 | 8,179,521 | NaN |
| In-process research and development | 10,000 | 1,773,606 | 515,996 | NaN |
| Depreciation | 2,807 | 6,841 | 6,840 | NaN |
| Other income | 433,227 | 325,435 | 1,006,772 | NaN |
| Pre-tax loss | NaN | -21,223,018 | NaN | NaN |
| Income tax benefit | NaN | 3,089 | NaN | NaN |
| Net loss | -7,206,990 | -5,708,542 | -2,115,831 | -13,401,734 |
| Depreciation | 2,807 | 6,841 | 6,840 | 13,680 |
| Stock-based compensation, including the issuance of restricted stock | 2,195,516 | 1,103,628 | 1,070,892 | 2,115,795 |
| Acquired in-process research and development assets | 10,000 | 1,773,606 | 515,996 | NaN |
| Prepaids and other current assets | -578,196 | -778,712 | 224,625 | -2,298,347 |
| Accounts payable | -154,713 | -50,580 | 180,358 | -656,784 |
| Accrued expenses | -1,382,199 | 849,207 | -1,199,979 | 1,450,625 |
| Deferred collaboration revenue | -251,147 | 240,001 | 635,746 | -421,500 |
| Net cash used in operating activities | -6,208,530 | -1,007,127 | -1,130,603 | -8,601,571 |
| Purchase of in-process research and development assets | 885,000 | 648,606 | 515,996 | NaN |
| Net cash used in investing activities | -885,000 | -648,606 | -515,996 | NaN |
| Proceeds from sale of common stock, net of offering costs | 10,995,387 | 20,348,653 | NaN | NaN |
| Proceeds from the exercise of stock options | NaN | 0 | 19,137 | 19,137 |
| Net cash provided by financing activities | 10,995,387 | 20,348,653 | 19,137 | 19,137 |
| Net increase (decrease) in cash and cash equivalents | 3,901,857 | 18,692,920 | -1,627,462 | -8,582,434 |
| Cash and cash equivalents as of beginning of the period | 46,822,786 | 28,129,866 | 38,339,762 | NaN |
| Cash and cash equivalents as of end of the period | 50,724,643 | 46,822,786 | 28,129,866 | NaN |
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)